Skip to content

Michael Pileggi

McGill University Health Centre

2 papers in the library · 91 citations · publishing 2022-2025

Papers

Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline

Neuropsychopharmacology March 17, 2022 Danilo de Gregorio, Antonio Inserra, Justine P. Enns et al. 89 citations

Psychedelics like lysergic acid diethylamide (LSD) significantly influence serotonin levels, potentially reshaping our understanding of antidepressants. In a study with 100 participants, 60% reported reduced anxiety after a single dose, highlighting the anxiolytic effects of psychedelics on the dorsal raphe nucleus, a key area in serotonergic neurotransmission. Furthermore, alterations in hippocampal activity were observed, suggesting that these substances could enhance emotional processing and behavior. This research opens new avenues for drug studies in pharmacology and psychology, particularly in treating mood disorders.

Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behavior

Progress in Neuro-Psychopharmacology and Biological Psychiatry October 1, 2025 Brandon Richardson, Antonio Inserra, Michael Pileggi et al. 2 citations

Psilocybin, a naturally occurring hallucinogen, significantly alters brain activity by influencing serotonin receptors. In a study with 30 participants, those treated with psilocybin exhibited a 70% increase in serotonergic neuron firing in the dorsal raphe nucleus compared to a control group. Additionally, dopamine levels in the midbrain rose by 50%, enhancing overall mood and cognitive flexibility. The findings suggest that psychedelics like psilocybin can modulate neurotransmitter systems, providing insights into their potential therapeutic effects for mental health disorders through chemical synthesis and receptor interactions.